3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC
China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III...
Cancer
Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based...
Abbisko’s Pimitinib Granted Priority Review for TGCT Treatment in China
Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its self-developed, highly selective small-molecule CSF-1R inhibitor,...
Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC
China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate...
CSPC Pharmaceutical Gains NMPA Approval for JMT106 Clinical Study in Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...
GSK’s Blenrep Receives Marketing Approval in Japan for Multiple Myeloma
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...
Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China
US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...
CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...
Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...
FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma
The US Food and Drug Administration (FDA) announced this week an indication extension approval for...
Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients
Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...
AbbVie’s Emrelis Granted FDA Accelerated Approval for NSCLC with High c-MET Overexpression
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AbbVie’s (NYSE: ABBV)...
Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer
Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...
CSPC Pharma Licenses Irinotecan Liposome Injection to Cipla for US Market
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has entered into a licensing agreement with India-headquartered...
Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242
Suzhou-based Medilink Therapeutics announced that it has received Investigational New Drug (IND) approval from the...
Betta Pharmaceuticals Secures Macau Approval for Ensartinib
China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...
RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints
China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...
Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...
Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...
RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis
China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...